Cannara Signs Long-Term Supply Deal With Curaleaf International

Agreement Terms and Volume Commitments

The supply agreement commits Cannara to deliver a minimum annual volume over a multi-year term, though neither party disclosed specific tonnage or revenue figures. Shipments begin Q4 2026. They'll scale through 2027, according to the press release. Cannara will supply both bulk dried flower and cannabis extracts to Curaleaf International's distribution network across the UK and Germany.

The contract includes tiered pricing based on volume thresholds and quality specifications. Cannara CEO Zohar Krivorot said the deal provides "revenue visibility and capacity utilization" for the company's 1.3-million-square-foot Valleyfield cultivation facility.

Curaleaf International's European Footprint

Curaleaf International operates medical cannabis distribution channels in the UK, Germany, and Portugal through its European subsidiaries. The company holds import licenses in all three jurisdictions and supplies over 200 pharmacies across Europe, according to its 2025 annual report.

This deal marks Curaleaf International's first publicly disclosed long-term supply contract with a Canadian LP. Historically, the company's sourced product through spot purchases and shorter-term agreements. For context on Curaleaf's broader international strategy, see the CannIntel topic hub on Curaleaf International Expansion.

Cannara's Export Strategy and Capacity

Cannara has operated below 40% capacity utilization since Q2 2025, according to its most recent earnings disclosure. The Valleyfield facility holds Health Canada licenses for cultivation, processing, and export. The company reported CAD $18.2 million in revenue for fiscal 2025, down 12% year-over-year, driven primarily by domestic wholesale price compression.

Krivorot framed the Curaleaf deal as a margin-accretive diversification play. "International contracts typically carry 15-20% higher gross margins than domestic wholesale," he said in the release. Cannara didn't disclose whether the agreement includes exclusivity provisions or minimum purchase obligations from Curaleaf.

Financial Implications for Both Parties

Neither company disclosed the contract's total value, but Cannara's press release described it as "material" under TSXV disclosure rules. Material contracts for TSXV issuers are generally defined as those representing more than 10% of annual revenue or significantly affecting financial condition.

For Cannara (market cap: CAD $42 million as of July 12, 2026), a deal exceeding CAD $1.8 million annually would meet the materiality threshold. Curaleaf International is a wholly owned subsidiary of Curaleaf Holdings (CSE: CURA), which reported USD $1.4 billion in consolidated revenue for fiscal 2025. The European segment contributed approximately 2% of total revenue.

What to Watch

The first shipment date and initial order volume will signal whether this deal moves the needle for Cannara's underutilized capacity. Investors will also watch whether Curaleaf International expands into additional European markets—Italy and France both launched medical frameworks in 2025—and whether Cannara can convert this anchor contract into additional export partnerships.

Cannara's next earnings call is scheduled for August 2026. Watch capacity utilization and international revenue mix.